PTC Therapeutics, Inc. (PTCT)

Market Cap	2.80B
Revenue (ttm)	900.45M
Net Income (ttm)	-479.52M
Shares Out	76.92M
EPS (ttm)	-6.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	721,738
Open	35.95
Previous Close	36.05
Day's Range	35.92 - 37.36
52-Week Range	17.53 - 40.69
Beta	0.65
Analysts	Hold
Price Target	36.21 (-0.6%)
Earnings Date	Oct 24, 2024

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pip...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 1,055
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT
• Website: https://www.ptcbio.com

Financial Performance

In 2023, PTC Therapeutics's revenue was $937.82 million, an increase of 34.20% compared to the previous year's $698.80 million. Losses were -$626.60 million, 12.1% more than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for PTCT stock is "Hold." The 12-month stock price forecast is $36.21, which is a decrease of -0.60% from the latest price.

Price Target

$36.21

(-0.60% downside)

Analyst Consensus: Hold